Injectable asthma drug resolves dangerous food allergies in one-third of children
In all, 36% of children treated with omalizumab (Xolair) for a year successfully ate full servings of allergy-triggering foods, according to phase 2 trial results presented Sunday at a meeting of the American Academy of Allergy, Asthma & Immunology in San Diego.
By comparison, only 19% of children could do the same when given a shorter round of omalizumab followed by months of oral immunotherapy, a treatment through which patients build tolerance by eating gradually increasing amounts of food allergens.
Further, early stage 3 results from the clinical trial found that children retained some resistance to food allergies even after they stopped taking omalizumab, researchers reported.
"This is the first time we've been able to directly compare these two treatments for multiple food allergies, and our study shows omalizumab was superior to oral immunotherapy," principal investigator Dr. Robert Wood, director of the Eudowood Division of Allergy, Immunology and Rheumatology at Johns Hopkins Children's Center, said in a news release.
Food allergies are common, affecting 8% of U.S. children and 10% of adults, researchers said in background notes.
Omalizumab works by binding to the antibodies that promote allergic reactions, rendering them inactive, researchers said in background notes.
The drug has been on the market since 2003, first approved by the U.S. Food and Drug Administration as a preventive treatment for allergic asthma, according to Drugs.com.
And based on early results from this clinical trial, the FDA approved omalizumab as a treatment for food allergies in adults and children as young as 1 year old, researchers said in background notes.
The stage 2 clinical trial involved 117 children with an average age of 7 who were allergic to peanuts and at least two other common food allergens -- milk, egg, cashew, wheat, walnut or hazelnut.
At week 44, the children were fed all three of their food allergens in amounts equivalent to about 20 peanuts or a half-cup of milk.
The lower results for children on oral immunotherapy were driven by the fact that more of these kids had to drop out of the study due to adverse reactions, researchers said.
About 88% of children treated with omalizumab finished the stage 2 trial, compared with 51% of those receiving oral immunotherapy, results show.
No children taking omalizumab experienced serious adverse reactions, compared with more than 30% of those treated with oral immunotherapy.
"We have demonstrated that there are multiple paths to living a safe life with food allergies," senior researcher Dr. Sharon Chinthrajah, acting director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford Medicine, said in a news release.
"This study is very encouraging because it shows that we have treatment choices for our patients that are safe and not too burdensome," she added.
Researchers at the AAAAI meeting also presented preliminary results from stage 3 of the clinical trial, which focused on the first 60 children in the study.
Stage 3 focused on different pathways that children with food allergies might take in real-world settings, after they've gained tolerance to trigger foods through omalizumab therapy.
Each of the children was assigned one of three strategies for each of their food allergens -- start eating the food, continue with oral immunotherapy or avoid the food.
These strategies were assigned based on how the kids responded to a food challenge following omalizumab treatment.
More than 80% of the plans began with the kids eating the foods to which they'd been allergic, results show.
The kids were then tracked for a year to see how they fared.
Preliminary results show that consumption of milk, egg and wheat had a greater success rate (61% to 70%) than peanuts and tree nuts (38% to 56%).
In most cases, kids ate declining amounts of their allergens during the follow-up period. Some adverse events occurred, including food reactions severe enough to require an epinephrine shot.
Stage 3 is ongoing, with completion expected this summer, researchers said.
"While the results of Stage 3 are still preliminary, the majority of the first 60 participants were able to successfully introduce allergenic foods into their diet after stopping omalizumab," lead researcher Dr. Jennifer Dantzer, a pediatric allergist at Johns Hopkins Children's Center, said in a news release.
"Omalizumab is currently approved in the U.S. for the reduction of allergic reactions that may occur with accidental exposures," Dantzer said. "These results indicate that omalizumab may have additional uses that may be valuable for patients, but the potential risks should be recognized."
Funding for the clinical trial came from Genentech and Novartis, the makers of omalizumab.
Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.
More information
The American Academy of Allergy, Asthma & Immunology has more about food allergies.
Copyright © 2025 HealthDay. All rights reserved.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
'The air was so dangerous in my Birmingham postcode I ended up on life support'
A Birmingham resident who lived near the city's landmark motorway, the Spaghetti Junction, has revealed how she ended up on life support. Named only as Jenny, the 75-year-old woman said she 'never realised how dangerous the air was' until she was hospitalised with life-threatening pneumonia. Traffic fumes and poor housing conditions were to blame for her deteriorating health, doctors told her at the time. Living next to the busiest motorway in Europe, she also found herself suffering regular asthma attacks just from stepping outside. Read more: Couple who starved their dog told RSPCA inspectors she was 'given to them by drug dealers' The retiree found her health drastically improved when she moved nearer to green spaces and away from the motorway. Speaking as part of a new Health Equals campaign this week, she said: 'I never realised just how dangerous the air I was breathing every day really was, I used to live near Spaghetti Junction, and would suffer regular asthma attacks just from stepping outside my door. "It wasn't until I ended up in hospital with pneumonia and on life support that doctors told me the traffic fumes and my poor housing conditions were to blame. "Everyone deserves clean air – not just those lucky enough to live near green spaces or away from busy roads. My health improved dramatically after I moved and started walking in parks. But not everyone has that choice." Her experience with air pollution comes as Health Equals, a coalition of 85 organisations, revealed World Health Organisation (WHO) air quality guidelines were breached in 35,000 neighbourhoods across Britain. Its report also outlined all 506 schools in Birmingham were in neighbourhoods failing the guidelines, putting 290,000 children at risk of serious long term health problems, including heart disease and stroke. The new findings are being released as part of Health Equals' Make Health Equal campaign, to highlight alarming health inequalities: where toxic air, alongside other issues including poor income, unstable jobs and unsafe homes, are contributing to an alarming 16-year gap in life expectancy across the UK. Health Equals is calling for a cross-government strategy that prioritises action on these essential building blocks of health, to stop lives being cut short. City environment boss Coun Majid Mahmood said: "Poor air quality is a major risk to public health, and that is why we are committed to improving the city's air through our clean air strategy. 'Data published in October 2023 showed that our work to address the air pollutant, nitrogen dioxide, is delivering results, with pollution levels in Birmingham city centre slashed by almost 40 per centr since 2016, driven in part by the introduction of the Clean Air Zone. 'Across the city, a dedicated air quality monitoring programme of potential 'hotspots' in Birmingham has found that all sites are within the annual mean air quality objective. This three year monitoring project concluded in 2024 and sought to identify any locations where concentrations of nitrogen dioxide might exceed the annual mean air quality objective. I am pleased to confirm our evidence suggests that outside of the city centre area, air quality concentrations are within legal limits. 'We also monitor particulate matter, both coarse and fine fractions (PM10 and PM2.5), and all of our sites continue to show compliance with legal limits set by Government. We will continue to work with Government to further drive down concentrations of fine particles as we know these are the largest risk to health and we have extended our monitoring network to this end. 'This is supported by our mission to install year-round air monitoring equipment in schools a key component in this. These monitors come in tandem with accompanying education resources and lesson plans helping to inspire a new generation of Clean Air champions. Our work in this area is underpinned further by projects like 'Car Free School Streets', which seeks to reduce emissions during rush hour, driven by readings from council monitoring data showing that the school gates are among the most polluted parts of the city. 'The school sensor programme has the co-benefit of providing monitoring data for fine particulate matter, recognised as a key pollutant in a range of adverse health outcomes such as heart disease, lung diseases and cancers. 'Furthermore, surplus revenues from the Clean Air Zone are feeding directly into our transport plan, enabling us to work in partnership with the West Midlands Combined Authority to support schemes related to active travel, improve public transport infrastructure, and manage demand in the city centre. 'Projects funded by Clean Air Zone revenues include a trial of hydrogen buses, upgrades to the University railway station and new stations on the Camp Hill line, as well as a number of projects within the Cross-City Bus scheme, the expansion of the Car Free School Streets programme, and development of the next phase of the Birmingham Cycle Revolution. Community grants for projects delivering against our priorities have also been provided through the Environment and Transport Neighbourhoods Fund (ETNF). 'Our work towards our clean air objectives continues with the recent launch of a consultation into the renewal of the city's Smoke Control Order, offering greater powers of enforcement against those who breach guidelines. This is just the latest step in our journey, which will not stop until we have achieved our objective of clean air for all residents.' Have you been affected by this. We would like to hear from you. You can contact us by emailing us on


Medscape
3 days ago
- Medscape
Improve Asthma by Targeting Common Triggers
This transcript has been edited for clarity. Asthma is a disease that affects 20% of the American population. This means that 20% of people wake up with shortness of breath, wheezing, or tightness in their chest, which is extremely uncomfortable. Common triggers that we can modify to help these patients include GERD (gastroesophageal reflux disease), which is the most common. Acid reflux can backflow into the lungs causing bronchoconstriction, shortness of breath, and wheezing, especially when someone is laying down. Treating GERD with diet modification and sometimes Pepcid or Protonix can be beneficial. Other triggers that we look for include postnasal drip or allergies. Allergies and postnasal drip can significantly impact asthma by once again leading to bronchoconstriction through mucus congestion, causing more buildup within the lungs and the smaller airways that can cause decreased breathing and shortness of breath. By treating them with Singulair — montelukast over the counter — Allegra, or even Flonase for nasal symptoms and sinus symptoms, this can significantly impact and decrease shortness of breath. The last trigger that we do look at is weight associated with obstructive sleep apnea. Sleep apnea can increase CO 2 within the body as ventilation decreases, and this can also lead to wheezing, shortness of breath, and increase asthma symptoms. Weight can significantly impact a patient's ability to inhale and exhale that can then, once again, induce asthmatic symptoms.


Medscape
4 days ago
- Medscape
Top 3 Chronic Urticaria Treatments Highlighted in Meta-Analysis
In managing antihistamine-refractory chronic urticaria, omalizumab and remibrutinib stand out among the most effective treatments across multiple patient-important outcomes, followed by dupilumab, which shows improvement in urticaria activity, according to a meta-analysis of 42 systemic treatments in 93 studies. All three treatments for chronic urticaria, a condition defined by wheal and itch symptoms persisting 6 weeks or more, have favorable safety profiles, according to the researchers, led by Alexandro W. L. Chu, MD, with the Department of Medicine and the Evidence in Allergy Group at McMaster University in Hamilton, Ontario, Canada. Findings were published in The Journal of Allergy and Clinical Immunology as part of an update of chronic urticaria guidelines for the American Academy of Allergy, Asthma & Immunology (AAAAI), American College of Allergy, Asthma & Immunology (ACAAI), and Joint Task Force on Practice Parameters (JTFPP). The meta-analysis examined patient-important outcomes beyond itch and wheal assessment such as angioedema, sleep quality, urticaria- and angioedema-related quality of life, and adverse events at the longest available time point. The researchers used measures including the 7-day Urticaria Activity Score, Chronic Urticaria Quality of Life Questionnaire and Angioedema Quality of Life Questionnaire. Dupilumab improves itch and wheals, 'but it is uncertain whether it improves angioedema or quality of life,' the researchers wrote. Cyclosporine, while it may be among the most effective, the analysis noted, may also be among the most harmful treatments with a high frequency of adverse events. In the intermediate range of effectiveness is low-dose omalizumab (doses below the standard 300 mg or administration less frequent than every 4 weeks) and that low dose also has a favorable safety profile, the data showed. 'Azathioprine, dapsone, hydroxychloroquine, mycophenolate, sulfasalazine, and vitamin D may improve outcomes, while benralizumab, quilizumab, and tezepelumab may not differ from placebo, though the evidence is uncertain,' the report stated. 'Findings were consistent across age groups and baseline severity and were robust to subgroup analyses.' Patients' comorbidities may also steer treatment selection, the authors wrote. 'For instance, patients with concomitant food allergies may favor omalizumab, while those with chronic rhinosinusitis with nasal polyposis or atopic dermatitis may favor dupilumab.' Remibrutinib Rachel Meltzer, MD, MPH, director of the Pruritus Clinic at Brigham and Women's Hospital and instructor in dermatology at Harvard Medical School, both in Boston, told Medscape Medical News the most important aspect of the meta-analysis is the side-by-side comparison of the treatments, particularly the comparison with the bruton tyrosine kinase inhibitor remibrutinib, which, she noted, is not yet approved by the FDA for any indication in dermatology. 'The only people who have any clinical experience with it are the people running the trials at the moment,' she said, and information from them indicates that 'remibrutinib does sound promising. The exciting thing is that it's an oral medicine and it seems to have a good safety and efficacy profile, whereas now, if someone fails our standard oral regimen, the move frequently has been to go to Zolair/omalizumab or less frequently in dermatology, cyclosporine.' 'Omalizumab has been approved for quite some time and that's been kind of the go-to if you need to escalate therapy if people fail the first-line high-dose antihistamines,' she said. Dupilumab, she said, 'wouldn't be the first thing I'd try unless someone had a comorbidity of atopic dermatitis or asthma or allergic rhinitis with nasal polyps,' she said. It was approved in April for chronic spontaneous urticaria. This is the first review of chronic urticaria treatments that has 'systematically analyzed the overall relative benefits and harms of all available options or appraised the evidence using robust and standardized approaches,' the authors wrote. This study was commissioned by the AAAAI and the ACAAI through the JTFPP. Several authors reported multiple ties to pharmaceutical companies, which are available with the full text. Meltzer reported no relevant financial relationships.